Precipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited)

Core Insights - Precipio, Inc. has achieved significant financial milestones in Q4 2024, indicating its ability to attain financial independence through positive cash flow from its pathology service division [1][2][3] - The company reported an Adjusted EBITDA of $0.4 million for Q4 2024, marking a positive operational performance [6] - Precipio experienced an increase of $0.3 million in cash during Q4 2024, primarily driven by cash flow from operations [6] Financial Performance - The company reported a net loss of $0.3 million for Q4 2024, with an Adjusted EBITDA of $0.4 million after accounting for non-cash stock-based compensation and other significant expenses [5][6] - The reconciliation of financial metrics shows that EBITDA was $0 for the quarter, highlighting the impact of non-cash costs on profitability [5][6] Management Commentary - The CEO emphasized that ending 2024 with positive financial results is a crucial step for the company, allowing it to focus on growth and value creation without relying on external capital [3] - Management believes that the current cash reserves and growth pipeline position the company to become profitable in the near future [2][3] Company Overview - Precipio is a healthcare biotechnology company specializing in cancer diagnostics, aiming to reduce misdiagnoses through innovative diagnostic products and services [7] - The company develops and commercializes proprietary technologies to improve diagnostic accuracy and laboratory workflow, ultimately enhancing patient outcomes [7]